Gynecologic Cancers
ESMO 2023: Adding a PARP Inhibitor to Chemoimmunotherapy in Advanced Endometrial Cancer
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
ESMO 2023: Adding a PARP Inhibitor to Chemoimmunotherapy in Advanced Endometrial Cancer
Maintenance Therapy With Selinexor in Patients With Endometrial Cancer
New Ovarian Cancer Risk-Control Guidance Suggests Early Surgical Intervention
ASCO 2022: Real-World Data on Maintenance Olaparib in BRCA-Mutated Ovarian Cancer
Rucaparib vs Standard-of-Care Chemotherapy for BRCA1/2-Mutated, Relapsed Ovarian Cancer
Dual Checkpoint Inhibition for Second-Line Treatment of Advanced Cervical Cancer